Clinical Trials Browser

Withdrawn × Hematologic Neoplasms × pembrolizumab × Clear all

NCT04605614 2022-06-09

64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression

Phase 1 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms

NCT04016116 2020-05-27

Dual PD-1 and JAK2 Inhibition in Hematological Malignancies

Phase 2 Withdrawn

Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms